Novartis Skin Treatment Drug Cosentyx Gets US FDA Approval
2023年11月1日 - 3:43PM
Dow Jones News
By Pierre Bertrand
Novartis said the U.S. Food and Drug Administration has approved
its drug Cosentyx for the treatment of the hidradenitis suppurativa
skin condition.
Novartis said late Tuesday that the approval of the drug is the
first of a new biologic treatment option for the condition in
nearly a decade.
The regulator's approval was based on data compiled in the
Sunshine and Sunrise Phase 3 study program, Novartis said.
Hidradenitis suppurativa is a chronic and systemic skin disease
which causes boil-like bumps that can burst and cause scarring, the
company said.
Novartis said there has previously only been one other treatment
option for the condition.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
November 01, 2023 02:28 ET (06:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
過去 株価チャート
から 4 2024 まで 5 2024
Novartis (NYSE:NVS)
過去 株価チャート
から 5 2023 まで 5 2024